Thank you very much;
you're only a step away from
downloading your reports.
Stocks: Insiders Buy at Epizyme and Intergrated Device Technology
Plus, purchases at Genocea Biosciences and Gladstone Investment and a sale at Epizyme.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • Celgene European Investment, a subsidiary of global biopharmaceutical company Celgene (NASDAQ:CELG), bought 340,000 shares of clinical stage biopharmaceutical company Epizyme (NASDAQ:EPZM) for $9,945,000. Epizyme also appears on the list of insider sales.
  • The clinical stage company Genocea Biosciences (NASDAQ:GNCA), which develops T cell vaccines, saw two insider purchases: Polaris Venture Management bought 465,640 shares of company stock for $5,587,680 while Director Stephen Hoffman bought 250,931 shares for $3,011,172.
  • Gregory Waters, CEO of low power, mixed signal semiconductor solutions company Integrated Device Technology (NASDAQ:IDTI), bought 100,000 shares of company stock for $1,051,504.
  • Terry Brubaker, COO of closed-end, non-diversified management investment company Gladstone Investment Corporation (NASDAQ:GAIN), bought 80,000 shares of company stock for $592,800.
Notable Sale:
  • MPM Bioventures IV, an investment fund of the private equity firm MPM Capital, sold 466,666 shares of Epizyme for $13,649,980.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
B
$9,945,000
2
BO
JB*
$8,400,000
3
BO
JB*
$5,587,680
4
DIR
JB*
$3,011,172
5
CEO,DIR
B
$1,051,504
6
CEO,DIR
JB*
$1,005,000
7
PR,SEC,DIR
JB*
$1,000,005
8
COO,DIR
B
$592,800
9
CB,PR,DIR
B
$531,720
10
PR
B
$186,099

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
CEO,DIR,BO
AS
$39,281,328
2
F,DIR
AS
$35,697,412
3
BO
S
$30,815,336
4
CEO,F,CB
AS
$26,762,276
5
BO
S
$13,649,980
6
CB,CEO,DIR
S
$4,698,235
7
CFO
AS
$4,461,692
8
CEO,PR,DIR
AS
$2,875,520
9
VP
S
$2,076,387
10
HR
S
$1,893,703

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
Stocks: Insiders Buy at Epizyme and Intergrated Device Technology
Plus, purchases at Genocea Biosciences and Gladstone Investment and a sale at Epizyme.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • Celgene European Investment, a subsidiary of global biopharmaceutical company Celgene (NASDAQ:CELG), bought 340,000 shares of clinical stage biopharmaceutical company Epizyme (NASDAQ:EPZM) for $9,945,000. Epizyme also appears on the list of insider sales.
  • The clinical stage company Genocea Biosciences (NASDAQ:GNCA), which develops T cell vaccines, saw two insider purchases: Polaris Venture Management bought 465,640 shares of company stock for $5,587,680 while Director Stephen Hoffman bought 250,931 shares for $3,011,172.
  • Gregory Waters, CEO of low power, mixed signal semiconductor solutions company Integrated Device Technology (NASDAQ:IDTI), bought 100,000 shares of company stock for $1,051,504.
  • Terry Brubaker, COO of closed-end, non-diversified management investment company Gladstone Investment Corporation (NASDAQ:GAIN), bought 80,000 shares of company stock for $592,800.
Notable Sale:
  • MPM Bioventures IV, an investment fund of the private equity firm MPM Capital, sold 466,666 shares of Epizyme for $13,649,980.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
B
$9,945,000
2
BO
JB*
$8,400,000
3
BO
JB*
$5,587,680
4
DIR
JB*
$3,011,172
5
CEO,DIR
B
$1,051,504
6
CEO,DIR
JB*
$1,005,000
7
PR,SEC,DIR
JB*
$1,000,005
8
COO,DIR
B
$592,800
9
CB,PR,DIR
B
$531,720
10
PR
B
$186,099

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
CEO,DIR,BO
AS
$39,281,328
2
F,DIR
AS
$35,697,412
3
BO
S
$30,815,336
4
CEO,F,CB
AS
$26,762,276
5
BO
S
$13,649,980
6
CB,CEO,DIR
S
$4,698,235
7
CFO
AS
$4,461,692
8
CEO,PR,DIR
AS
$2,875,520
9
VP
S
$2,076,387
10
HR
S
$1,893,703

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
Stocks: Insiders Buy at Epizyme and Intergrated Device Technology
Plus, purchases at Genocea Biosciences and Gladstone Investment and a sale at Epizyme.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Notable Purchases:
  • Celgene European Investment, a subsidiary of global biopharmaceutical company Celgene (NASDAQ:CELG), bought 340,000 shares of clinical stage biopharmaceutical company Epizyme (NASDAQ:EPZM) for $9,945,000. Epizyme also appears on the list of insider sales.
  • The clinical stage company Genocea Biosciences (NASDAQ:GNCA), which develops T cell vaccines, saw two insider purchases: Polaris Venture Management bought 465,640 shares of company stock for $5,587,680 while Director Stephen Hoffman bought 250,931 shares for $3,011,172.
  • Gregory Waters, CEO of low power, mixed signal semiconductor solutions company Integrated Device Technology (NASDAQ:IDTI), bought 100,000 shares of company stock for $1,051,504.
  • Terry Brubaker, COO of closed-end, non-diversified management investment company Gladstone Investment Corporation (NASDAQ:GAIN), bought 80,000 shares of company stock for $592,800.
Notable Sale:
  • MPM Bioventures IV, an investment fund of the private equity firm MPM Capital, sold 466,666 shares of Epizyme for $13,649,980.
For more insider trades, see the charts below.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
B
$9,945,000
2
BO
JB*
$8,400,000
3
BO
JB*
$5,587,680
4
DIR
JB*
$3,011,172
5
CEO,DIR
B
$1,051,504
6
CEO,DIR
JB*
$1,005,000
7
PR,SEC,DIR
JB*
$1,000,005
8
COO,DIR
B
$592,800
9
CB,PR,DIR
B
$531,720
10
PR
B
$186,099

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
CEO,DIR,BO
AS
$39,281,328
2
F,DIR
AS
$35,697,412
3
BO
S
$30,815,336
4
CEO,F,CB
AS
$26,762,276
5
BO
S
$13,649,980
6
CB,CEO,DIR
S
$4,698,235
7
CFO
AS
$4,461,692
8
CEO,PR,DIR
AS
$2,875,520
9
VP
S
$2,076,387
10
HR
S
$1,893,703

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
EDITOR'S PICKS
 
WHAT'S POPULAR